Flockhart D
Flockhart D
Professor of Medicine, Indiana University School of Medicine
Verified email at
Cited by
Cited by
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin, Z Desta, V Stearns, B Ward, H Ho, KH Lee, T Skaar, AM Storniolo, ...
Journal of the National Cancer Institute 97 (1), 30-39, 2005
Clinical significance of the cytochrome P450 2C19 genetic polymorphism
Z Desta, X Zhao, JG Shin, DA Flockhart
Clinical pharmacokinetics 41, 913-958, 2002
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns, MD Johnson, JM Rae, A Morocho, A Novielli, P Bhargava, ...
Journal of the National Cancer Institute 95 (23), 1758-1764, 2003
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz, JM Rae, VJ Suman, SL Safgren, MM Ames, DW Visscher, ...
Journal of Clinical Oncology 23 (36), 9312-9318, 2005
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6
Z Desta, BA Ward, NV Soukhova, DA Flockhart
Journal of Pharmacology and Experimental Therapeutics 310 (3), 1062-1075, 2004
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with …
BP Schneider, M Wang, M Radovich, GW Sledge, S Badve, A Thor, ...
Journal of Clinical Oncology 26 (28), 4672, 2008
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate …
BA Ward, JC Gorski, DR Jones, SD Hall, DA Flockhart, Z Desta
Journal of Pharmacology and Experimental Therapeutics 306 (1), 287-300, 2003
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
MP Goetz, SK Knox, VJ Suman, JM Rae, SL Safgren, MM Ames, ...
Breast cancer research and treatment 101, 113-121, 2007
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment
S Borges, Z Desta, L Li, TC Skaar, BA Ward, A Nguyen, Y Jin, ...
Clinical Pharmacology & Therapeutics 80 (1), 61-74, 2006
Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen
MD Johnson, H Zuo, KH Lee, JP Trebley, JM Rae, RV Weatherman, ...
Breast cancer research and treatment 85, 151-159, 2004
Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3': 5'-monophosphate-dependent protein kinase
JD Corbin, PH Sugden, L West, DA Flockhart, TM Lincoln, D McCarthy
Journal of Biological Chemistry (USA), 1978
Drug interactions: cytochrome P450 drug interaction table
DA Flockhart
Indiana University School of Medicine 2010, 2007
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
RA Wilke, DW Lin, DM Roden, PB Watkins, D Flockhart, I Zineh, ...
Nature reviews Drug discovery 6 (11), 904-916, 2007
Regulatory mechanisms in the control of protein kinase
DA Flockhart, JD Corbin
Critical reviews in biochemistry 12 (2), 133-186, 1982
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays
JM Rae, MD Johnson, ME Lippman, DA Flockhart
Journal of Pharmacology and Experimental Therapeutics 299 (3), 849-857, 2001
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
YC Lim, Z Desta, DA Flockhart, TC Skaar
Cancer chemotherapy and pharmacology 55, 471-478, 2005
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer
NL Henry, F Azzouz, Z Desta, L Li, AT Nguyen, S Lemler, J Hayden, ...
Journal of Clinical Oncology 30 (9), 936, 2012
Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants
JE Tanus-Santos, M Desai, DA Flockhart
Pharmacogenetics and Genomics 11 (8), 719-725, 2001
Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications
S Bernard, KA Neville, AT Nguyen, DA Flockhart
The oncologist 11 (2), 126-135, 2006
Pharmacogenomics: challenges and opportunities
DM Roden, RB Altman, NL Benowitz, DA Flockhart, KM Giacomini, ...
Annals of internal medicine 145 (10), 749-757, 2006
The system can't perform the operation now. Try again later.
Articles 1–20